semaglutide for people without diabetes What if you could get the benefits of a GLP-1 medication — the needle, without the weekly injection, without the sting — simply by taking a pill? That is no longer The Potential of Semaglutide Once-Weekly

According to current study findings, the guideline from ADA 2023 has designated SGLT-2i and GLP-1 RAs as first-line drugs for T2DM patients with established ASCVD or high cardiovascular risk, and metformin is no longer recommended as first-line therapy for T2DM patients with high cardiovascular risk due to its neutral HF benefits

Real-world and observational evidence have been consistently encouraging

So even normal GLP-1 levels are no match for foods designed to override them

Microdosing approaches A growing number of researchers explore semaglutide at doses below the standard 0.25mg starting point

Pencek R, Marmon T, Roth JD, Liberman A, Hooshmand-Rad R, Young MA (2016) Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers